Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing Exelixis' Zanzalintinib + Atezolizumab (STELLAR-303 Trial) Phase 3 Results in Metastatic Colorectal Cancer as Presented at ESMO 2025

Ticker(s): EXEL

Who's the expert?

Institution: Sarah Cannon Research Institute UK (London, UK)

Senior Medical Oncologist at Sarah Cannon UK and The Royal Marsden and Institute of Cancer Research.
Manages over 50 patients annual with colorectal cancer
Investigator in STELLAR 303 pivotal trial evaluating Zanzalintinib in combination with an immune checkpoint inhibitor. Expert in translational oncology and early-phase clinical trials, with over 160 peer-reviewed publications exploring biomarkers, liquid-biopsy, and novel therapeutics in mCRC and GI malignancies.

Interview Goal

To gain a deeper understanding of Exelixis' zanzalintinib and atezolizumab as a potential treatment for metastatic colorectal cancer. Looking at OS Benefit and Clinical Implications

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.